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Mismatch repair deﬁciency (dMMR) or microsatellite instability (MSI) has been reported as a predictive
biomarker for responses to programmed death-1 (PD-1) blockade in metastatic colorectal cancer. A high
response rate to anti-PD-1 therapy was observed in other cancer types with MSI. We report a
chemotherapy-refractory metastatic gastric cancer patient with dMMR and MSI who responded
remarkably well to pembrolizumab, a PD-1 monoclonal antibody. The satisfactory objective response has
lasted for more than 24 months as of this report.
© 2016 The Chinese Oncology Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Gastric cancer is a major cause of cancer deaths worldwide,
particularly in East Asia.1 Metastatic gastric cancer is associated
with poor outcomes. The median overall survival of metastatic
gastric cancer ranges from 9 to 13 months despite treated with
systemic chemotherapy, anti-human epidermal growth factor re-
ceptor (HER) 2 therapy (trastuzumab) for HER2-positive disease,
and anti-vascular endothelial growth factor receptor (VEGFR) 2
monoclonal antibody (ramucirumab) in second-line treatments.2e4
Since 2011, a novel class of anticancer therapy, immune checkpoint
blockade, has been introduced, leading to a paradigm shift in
oncology. Patients with metastatic gastric cancer are among those
with fatal diseases who may beneﬁt from these agents.
Cancer cells can evade the human immune system by regulating
immune checkpoint molecules. The programmed death 1 (PD-1)National Taiwan University
Taiwan.
ncology Society.
Production and hosting by Elsevi
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osatellite instability, Journalprotein, an inhibitory immune checkpoint molecule that has been
extensively studied, downregulates immune responses by binding
to its ligands, PD-L1 and -L2.5 Monoclonal antibodies against PD-1,
including pembrolizumab and nivolumab, have been approved by
the US Food and Drug Administration for treating melanoma, lung
cancer, and lymphoma. PD-1 blockade is effective in a fraction of
patients with metastatic gastric cancer.6 Until now, an ideal
biomarker for predicting the response to PD-1 blockade remains
elusive in metastatic gastric cancer.
Mismatch repair-deﬁcient cancers are rich in lymphocyte inﬁl-
tration, which indicates an immune response.7 This ﬁnding led to
the hypothesis that such tumors more favorably respond to im-
mune checkpoint blockade. Le et al reported an association be-
tweenmismatch repair deﬁciency (dMMR) and the response to PD-
1 blockade in metastatic colorectal cancer (CRC). Patients with
mismatch repair-deﬁcient CRC showed a substantially higher
response rate to PD-1 blockade than did those with proﬁcient
mismatch repair (pMMR) function.8 Several other dMRR cancers
have shown high response rates to anti-PD-1 therapy.9 Herein, we
report a chemotherapy-refractory metastatic gastric cancer patient
with dMMR and microsatellite instability (MSI) who showed a
satisfactory response to pembrolizumab (formerly MK-3475), aer B.V. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. CT performed before pembrolizumab treatment. The largest diameter of the
perivertebral tumor was 4.8 cm.
Fig. 2. CT performed at the time of the most favorable response after pembrolizumab
treatment. The perivertebral tumor was hardly visible.
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24 months.
2. Case report
A 66-year-old man visited the outpatient clinic at National
Taiwan University Hospital in September 2009 after experiencing
difﬁculty in swallowing, particularly when consuming solid food,
for 3 weeks. The patient did not report marked weight loss, vom-
iting, or pain in the chest and abdomen. He did not smoke ciga-
rettes or consume alcohol. The patient mentioned no history of
cancer in ﬁrst and second-degree relatives. No remarkable ﬁndings
were observed on initial examinations at the clinic. Esophagogas-
troduodenoscopy showed an ulcerative mass with irregular bor-
ders at the gastric cardia, with lower esophageal involvement. The
epicenter of the tumor was greater than 5 cm away from the
esophagogastric junction. Biopsy of the mass showed adenocarci-
noma, diffusely positive for cytokeratine but negative for CK7,
CK20, and CDX2. Serial imaging studies for staging did not reveal
distant metastasis. The patient underwent thoracoscopic esoph-
agectomy and gastric tube reconstruction (Ivor Lewis procedure) in
October 2009. The pathological stage was pT4aN1M0, stage IIIA.
Adjuvant chemotherapy with cisplatin (60 mg/m2 on day 1 every 2
weeks) plus infusional 5-ﬂuorouracil (5-FU) and leucovorin
(2200mg/m2 and 300mg/m,2 respectively, on day 1 every 2weeks)
was administered from December 2009 to March 2010. In February
2011, computed tomography (CT) of the abdomen revealed multi-
ple nodular lesions at the peritoneum and mesentery, which were
later histologically proven as metastatic adenocarcinoma. The pa-
tient received salvage chemotherapy with oxaliplatin (85mg/m2 on
day 1) and capecitabine (1250 mg/m2 BID on days 1e14 every 2
weeks) from June 2011 to March 2012. Treatment assessment in
April 2011 revealed progressive disease, and second-line chemo-
therapy with paclitaxel (80 mg/m2 on day 1) and infusional 5-FU
plus leucovorin (2600 and 300 mg/m,2 respectively, on day 1)
every 2 weeks was administered fromMay 2012. A new metastatic
tumor in the spleen was observed in July 2012, and the patient
underwent debulking surgery of the peritoneal tumors and sple-
nectomy in August 2012, as the tumor was limited in the abdomen.
Metastasis at S6 of the liver was reported in August 2013; therefore,
the patient underwent radiofrequency ablation in August and
November 2013. In February 2014, CT revealed a new lymphade-
nopathy at the right perivertebral space next to the aortic hiatus.
The patient started receiving 10 mg/kg pembrolizumab every 2
weeks in April 2014.6 Eight weeks after therapy initiation, the
lymphadenopathy, which was considered the target lesion, shrunk
from 4.8 cm (Fig. 1) to 3.2 cm, representing a 33% reduction of
relative to the pretreatment size. In April 2016, the highest reduc-
tion (59%) of the target lesionwas achieved (Fig. 2). The response to
pembrolizumab was durable, lasting for more than 24 months, and
is still ongoing. The treatment was well tolerated by the patient,
and no adverse effects other than grade 1 fatigue, elevation of
alkaline phosphatase, and hypothyroidism were observed during
the treatment period. The patient completed 2 years of pem-
brolizumab treatment in April 2016. He is currently alive and is not
receiving any active anticancer treatment.
3. Analysis of mismatch repair function and results
Biopsy of the recurrent tumor at the perivertebral region was
performed. MMR function was assessed by analyzing the micro-
satellite loci through polymerase chain reaction (PCR) and immu-
nohistochemical (IHC) staining of proteins.
Analysis of microsatellite instability: Multiplex PCR ampliﬁca-
tion of 5 mononucleotide microsatellite loci was performed usingPlease cite this article in press as:Wu T-H, et al., Durable response to progr
with mismatch repair deﬁciency and microsatellite instability, Journal
j.jcrpr.2016.11.001the MSI Analysis System (Promega).10 Ampliﬁcation products were
analyzed using the ABI 3500Dx capillary electrophoresis instru-
ment (Applied Biosystems, Foster City, CA, USA). The neoplasm is
designated as having high MSI (MSI-H) when novel allele lengths
are identiﬁed in the neoplastic cells compared with normal or
germline cells at 2 or more microsatellite loci.11
Immunohistochemical staining of DNA mismatch repair pro-
teins: IHC staining of MLH1 (clone ES05, 1:100; Dako), MSH2 (clone
FE11, 1:100, Dako), PMS2 (clone EP51, 1:50, Dako), andMSH6 (clone
EP49, 1:200, Dako) was performed using an automated immunos-
tainer (BENCHMARK® XT, Ventana Medical System, Tucson, AZ,
USA) and reviewed by 2 board-certiﬁed pathologists.
Results: MSI was observed in all 5 mononucleotide microsatel-
lite loci compared with tumor tissues and peripheral blood,
consistent with MSI-H (Fig. 3). IHC staining revealed that the tumor
was negative for MLH1 and PMS2 (Fig. 4).
4. Discussion
Cancer cells can evade immune surveillance through several
mechanisms. One of the most crucial mechanisms is suppressing
immune responses by expressing immune checkpoints. Immune
checkpoints have been extensively studied in the past few years,
resulting in the development of immune checkpoint blockade.12
Pembrolizumab (formerly MK-3475), a humanized monoclonalammed death-1 (PD-1) blockade in ametastatic gastric cancer patient
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Fig. 3. MSI, MSI was observed in all 5 mononucleotide microsatellite loci, consistent
with MSI-H. N: peripheral blood; T: tumor. Arrows indicate alleles with shifting.
Fig. 4. IHC staining of (A) MLH1, (B) MSH2, (C) MSH6, and (D) PMS2 at 400  Tumor cells lacked MLH1 and PMS2 MMR protein expression.
T.-H. Wu et al. / Journal of Cancer Research and Practice xxx (2016) 1e4 3IgG4 antibody that targets immune checkpoint molecule: PD-1, has
shown durable responses in melanoma, non-small- cell lung can-
cer, and several other cancer types.13e15 Emerging data suggest that
approximately 20% of patients also respond to PD-1 blockade.9,16
However, identify a useful predictive biomarker for anti-PD-1
blockade in gastric cancer is challenging.
Programmed cell death ligand 1 (PD-L1) expression in tumor
and invasive borders may potentially predict the response to PD-1
blockade; however, the predictability and optimal cutoff threshold
remain controversial and inconclusive.14,17e19 Muro et al reported
the efﬁcacy of pembrolizumab in pretreated patients with PD-L1
expressing (distinctive stromal or 1% tumor nest cell PD-L1
staining) recurrent or metastatic adenocarcinoma of the stomach
or gastroesophageal junction. The objective response rate was 22%,Please cite this article in press as:Wu T-H, et al., Durable response to progr
with mismatch repair deﬁciency and microsatellite instability, Journal
j.jcrpr.2016.11.001and the median response duration was 24 weeks among the 36
enrolled patients who were treated with pembrolizumab.6 PD-L1
appears to be a suboptimal predictive biomarker for PD-1
blockade in gastric cancer.
Virus-associated malignancies more favorably respond to im-
mune checkpoint blockade. Higher expression of PD-L1 induced by
viral infection and more tumor inﬁltrating lymphocytes in the
microenvironment are hypothetic mechanisms underlying the
more favorable responses.20,21 Pembrolizumab is effective against
virus-associated malignancies, such as nasopharyngeal carcinoma,
Merkel cell carcinoma, and human papillomavirus-associated
oropharyngeal cancer.22 A small fraction of gastric adenocarci-
noma is associated with EpsteineBarr virus (EBV).23 However, the
response to immune checkpoint blockade in EBV-associated gastric
adenocarcinoma is unclear, and EBV-encoded small RNA is not
established as a biomarker for immune checkpoint blockade in
gastric cancer.
Deﬁcient MMR (dMMR) causes MSI-H that results in a 10e100-
fold increase in mutational load. Studies have reported that tumors
with a high mutational load more favorably respond to immunecheckpoint blockade.24,25 Moreover, Le et al revealed that meta-
static colon cancers harboring MSI-H favorably respond to PD-1
blockade, with an objective response rate of 40%.8
Approximately 15%e20% of patients in all stages of gastric
cancer demonstrate the MSI-H phenotype.26,27 MSI-H is associated
with favorable prognosis in gastric cancer,28,29 whereas its pre-
dictability of the response to immune checkpoint blockade is
controversial. At the annual meeting of the American Society of
Clinical Oncology in 2016, Le et al reported the results of a subse-
quent cohort of various cancer types other than CRC with dMMR
treated with pembrolizumab. Two of the three enrolled patients
with advanced gastric cancer responded to PD-1 blockade; one had
a complete response and one had a partial response.9 In contrast,
Chen et al reported a patient with MMR-proﬁcient (pMMR) andammed death-1 (PD-1) blockade in ametastatic gastric cancer patient
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response to pembrolizumab. This result indicates that pMMR and
an MSS status may not fully predict resistance to PD-1 blockade in
gastric cancer, as suggested by a previous study on CRC by Le et al,
in which none of the 18 MSS patients responded to PD-1 blockade.8
We herein report a patient with dMMR and MSI-H metastatic
gastric cancer who responded favorably and durably to PD-1
blockade. This patient, along with the previous two demonstrated
by Le et al,9 are up-to-date the only 3 MMR gastric cancer patients
who responded well to PD-1 blockade. Response to PD-1 blockade
was also observed in patients with pMMR and MSS gastric can-
cer30; therefore, the clinical implications of MMR function in gastric
cancer require further investigation.
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